Departments of Public Health Sciences (Drs Espeland, Rapp, Shumaker, and Dailey, and Ms Hogan) and Psychiatry and Behavioral Medicine (Dr Rapp), Wake Forest University School of Medicine, Winston-Salem, NC; Women’s Health Center, University of Nevada School of Medicine, Reno (Dr. Brunner); Division of Preventive Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass (Dr Manson); Departments of Psychology and Obstetrics and Gynecology, McGill University, Montreal, Quebec (Dr Sherwin); Department of Medicine, George Washington University, Washington, DC (Dr Hsia); Division of Clinical Epidemiology, Hennepin County Medical Center, Minneapolis, Minn (Dr. Margolis); Department of Epidemiology, University of Iowa College of Medicine, Iowa City (Dr Wallace); Department of Obstetrics and Gynecology and Women’s Health, Montefiore Medical Center, Bronx, NY (Dr. Freeman); and Center for Women’s Health, Baylor College of Medicine, Houston, Tex (Dr Hays).

El Dr. Espeland ha recibido honorarios de Wyeth Pharmaceuticals. El Dr. Shumaker es un consultor de Wyeth and Pfizer. El Dr. Sherwin es miembro de Continuing Medical Education Hormone Council for Wyeth Pharmaceuticals. El Dr. Freeman recibe soporte financiero de y es un conferencista del grupo de Wyeth Pharmaceuticals.

El Dr. Espeland tuvo libre acceso a los datos del estudio, y asumió la responsabilidad y la veracidad del análisis de los mismos.

Espeland, Rapp, Shumaker, Manson, Margolis, Dailey, Hays. Obtención de los datos: Rapp, Shumaker, Brunner, Manson, Hsia, Margolis, Wallace, Dailey, Freeman, Hays.

Análisis e interpretación de los datos: Espeland, Rapp, Shumaker, Manson, Sherwin, Hsia, Margolis, Hogan, Wallace, Dailey.

Diagramación del manuscrito: Espeland, Rapp, Shumaker, Brunner, Sherwin, Hsia, Dailey, Freeman.

Expertos en estadística: Espeland, Hogan.

Obtención de fondos: Espeland, Shumaker, Manson, Wallace.

Soporte administrativo, técnico o material: Espeland, Rapp, Shumaker, Brunner, Manson, Sherwin, Margolis, Wallace, Dailey, Freeman, Hays.

Supervisión del estudio: Espeland, Rapp, Shumaker, Hsia, Margolis, Hays.

Fondos/Financiación: este estudio fue creado por Wyeth Farmaceuticals como un estudio anexo al WHI. El programa del WHI fue creado por the National Heart, Lung, and Blood Institute, US Department of Health and Human Services. El creador y financiador del estudio aportó la droga del estudio para el WHI y los fondos para el WHIMS.

Papel de los patrocinadores: Wyeth Pharmaceuticals y el National Heart, Lung, and Blood Institute no participaron ni en el diseño ni en la conducción del estudio, tampoco en la colección, análisis, revisión, y aprobación del manuscrito. Los autores del WHIMS son los únicos responsables de esos aspectos.

1. Barker A, Jones R, Jennison C. A prevalence study of age-associated memory impairment. Br J Psychiatry. 1995; 167: 642-648.

2. Coria F, Gomez de Caso JA, Minue´s L et al. Prevalence of age-associated memory impairment and dementia in a rural community. J Neurol Neurosurg Psychiatry. 1993; 56: 973-976.

4. Toran-Allerand CD. Organotypic culture of the developing cerebral cortex and hypothalamus: relevance to sexual differentiation. Psychoneuroendocrinology. 1991; 16: 7-24.

5. Foy MR, Henderson VW, Berger TW, Thompson RF. Estrogen and neural plasticity. Curr Dir Psychol Sci. 2000; 9: 148-152.

6. Goodman Y, Bruce AJ, Cheng B, Mattson MP. Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid betapeptide toxicity in hippocampal neurons. J Neurochem. 1996; 66: 1836-1844.

7. Sherwin BB. Estrogen and cognitive functioning in women. Endocr Rev. 2003; 24: 133-151.

8. Yaffe K, Sawaya G, Lieberburg I, Grady D. Estro-gen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA. 1998; 279: 688-695.

9. LeBlanc ES, Janowsky J, Chan BK, Nelson HD. Hormone replacement therapy and cognition: systematic review and metaanalysis. JAMA. 2001; 285: 1489-1499.

10. Hogervorst E, Yaffe K, Richards M, Huppert F. Hormone replacement therapy for cognitive function in postmenopausal women. Cochrane Database Syst Rev [serial online]. 2002: CD003122.

12. Mitchell JL, Cruickshanks KJ, Klein BE, et al. Postmenopausal hormone therapy and its association with cognitive impairment. Arch Intern Med. 2003; 163: 2485-2490.

13. The Women’s Health Initiative Study Group. Design of the Women’s Health Initiative clinical trial and observational study. Control Clin Trials. 1998; 19: 61- 109.

14. Shumaker SA, Reboussin BA, Espeland MA et al. The Women’s Health Initiative Memory Study (WHIMS): a trial of the effect of estrogen therapy in preventing and slowing the progression of dementia.

Control Clin Trials. 1998; 19: 604-621.

15. Shumaker S, Legault C, Rapp S et al. The effects of estrogen plus progestin on the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women’s Health Initiative Memory Study. JAMA. 2003; 289: 2651-2662.

16. Rapp SR, Espeland MA, Shumaker SA et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003; 289: 2663-2672.

17. The Women’s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative Randomized Controlled Trial. JAMA. 2004; 291: 1701-1712.

18. Shumaker SA, Legault C, Kuller L, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women’s Health Initiative Memory Study. JAMA. 2004; 291: 2947-2958.

21. Teng EL, Chui HC, Gong A. Comparisons between the Mini-Mental State Exam (MMSE) and its modified version: the 3MS test. In: Hasegawa K, Homma A, eds. Psychogeriatrics Biomedical and Social Advances. Tokyo, Japan: Excerpta Medica; 1990; 189-192.

22. Bravo G, Hebert R. Reliability of the ModifiedMini-Mental State Examination in the context of a twophase community prevalence study. Neuroepidemiology. 1997; 16: 141-148.

23. Tombaugh TN, McDowell I, Kristansson B, Hubley AM. Mini-Mental State

Examination (MMSE) and the Modified MMSE(3MS): a psychometric comparison and normative data. Psychol Assess. 1996; 8: 48-59.

24. McDowell I, Kristjansson B, Hill GB, Hebert R. Community screening for dementia: the Mini-Mental State Exam (MMSE) and Modified Mini-Mental State Exam (3MS) compared. J Clin Epidemiol. 1997; 50: 377-383.

26. Bland RC, Newman SC. Mild dementia or cognitive impairment: the Modified Mini-Mental State examination (3MS) as a screen for dementia. Can J Psychiatry. 2001; 46: 506-510.

27. Graham JE, Rockwood K, Beattie BL et al. Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet. 1997; 349: 1793-1796.

28. Kuller LH, Lopez OL, Newman A et al. Risk factors for dementia in the cardiovascular health cognition study. Neuroepidemiology. 2003; 22: 13-22.

29. Littell RC, Milliken GA, Stroup WW, Wolfinger RD. SAS System for Mixed Models. Cary, NC: SAS Institute Inc; 1996.

30. Zhang J, Yu KF. What’s the relative risk: amethod of correcting the odds ratio in cohort studies of common outcomes. JAMA. 1998; 280: 1690-1691.

31. Linzmayer L, Semlitsch HV, Saletu B, et al. Doubleblind, placebo-controlled psychometric studies on the effects of a combined estrogen-progestin regimen versus estrogen alone on performance, mood and personality of menopausal syndrome patients. Arzneimittelforschung. 2001; 51: 238-245.

32. Rice MM, Graves AB, McCurry SM et al. Postmenopausal estrogen and estrogenprogestin use and 2-year rate of cognitive change in a cohort of older Japanese American women. Arch Intern Med. 2000; 160: 1641-1649.

34. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative Randomized Controlled Trial. JAMA. 2002; 288: 321-333.

35. Matthews K, Kuller LH, Wing RR et al. Prior to use of estrogen replacement therapy, are users healthier than nonusers? Am J Epidemiol. 1996; 143: 971-978.

37. Rapp PR, Morrison JH, Roberts JA. Cyclic estrogen replacement improves cognitive function in aged ovariectomized rhesus monkeys. J Neurosci. 2003; 23: 5708-5714.

39. Zandi PP, Carlson MC, Plassman BL et al. Hormone replacement therapy and the incidence of Alzheimer disease in older women: the Cache County Study. JAMA. 2002; 288: 2123-2129.

40. Wysowski DK, Golden L, Burke L. Use of menopausal estrogens and medroxyprogesteronein the United States, 1982-1992. Obstet Gynecol. 1995; 85: 6-10.